Context Therapeutics (CNTX) Financials

Context Therapeutics logo
$0.16 -0.01 (-4.51%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$0.16 0.00 (-0.62%)
As of 11/20/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Context Therapeutics

Annual Income Statements for Context Therapeutics

This table shows Context Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
6.64 -10 -15 -24 -27 -36
Consolidated Net Income / (Loss)
6.64 -10 -15 -24 -27 -36
Net Income / (Loss) Continuing Operations
6.64 -10 -15 -24 -27 -36
Total Pre-Tax Income
6.64 -11 -15 -24 -27 -36
Total Operating Income
-2.57 -11 -15 -25 -30 -40
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
2.57 11 15 25 30 40
Selling, General & Admin Expense
0.93 3.63 7.79 7.29 7.22 7.85
Research & Development Expense
1.64 6.89 7.59 18 23 32
Total Other Income / (Expense), net
9.22 -0.05 0.55 1.11 3.20 3.58
Interest & Investment Income
- - - 1.16 3.20 3.38
Other Income / (Expense), net
9.88 0.01 -0.00 -0.06 -0.00 0.20
Basic Earnings per Share
$3.07 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Weighted Average Basic Shares Outstanding
348.37K 2.83M 15.97M 15.97M 58.42M 95.19M
Diluted Earnings per Share
($3.96) ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Weighted Average Diluted Shares Outstanding
2.05M 2.83M 15.97M 15.97M 58.42M 95.19M
Weighted Average Basic & Diluted Shares Outstanding
- 15.97M 15.97M 15.97M 89.70M 91.88M

Quarterly Income Statements for Context Therapeutics

This table shows Context Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Consolidated Net Income / (Loss)
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Net Income / (Loss) Continuing Operations
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Total Pre-Tax Income
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Total Operating Income
-3.82 -3.09 -19 -4.31 -5.53 -9.76 -11 -14 -9.34 -15 -7.96
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
3.82 3.09 19 4.31 5.53 9.76 11 14 9.34 15 7.96
Selling, General & Admin Expense
1.85 1.70 1.88 1.79 2.07 1.93 1.89 1.96 2.33 2.44 2.24
Research & Development Expense
1.97 1.38 17 2.52 3.46 7.83 8.72 12 7.02 13 5.72
Total Other Income / (Expense), net
0.16 0.83 1.24 0.97 0.95 0.93 0.92 0.78 0.66 0.41 0.34
Interest & Investment Income
0.15 0.84 1.24 0.96 0.96 0.90 0.83 0.68 0.52 0.42 0.33
Other Income / (Expense), net
0.00 -0.01 -0.00 0.00 -0.01 0.03 0.08 0.10 0.14 -0.01 0.01
Basic Earnings per Share
($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09) ($0.15) ($0.08)
Weighted Average Basic Shares Outstanding
15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M 95.18M 95.18M
Diluted Earnings per Share
($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09) ($0.15) ($0.08)
Weighted Average Diluted Shares Outstanding
15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M 95.18M 95.18M
Weighted Average Basic & Diluted Shares Outstanding
75.00M 75.00M 75.00M 89.70M 89.70M 89.70M 91.88M 91.88M 91.88M 91.88M 91.88M

Annual Cash Flow Statements for Context Therapeutics

This table details how cash moves in and out of Context Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.11 49 -14 -21 80 -28
Net Cash From Operating Activities
-1.03 -8.80 -14 -21 -15 -26
Net Cash From Continuing Operating Activities
-1.03 -8.80 -14 -21 -15 -26
Net Income / (Loss) Continuing Operations
6.64 -10 -15 -24 -27 -36
Consolidated Net Income / (Loss)
6.64 -10 -15 -24 -27 -36
Depreciation Expense
- 0.00 0.01 0.01 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income
-9.00 3.88 1.38 1.08 16 3.44
Changes in Operating Assets and Liabilities, net
1.32 -2.22 -0.20 1.78 -3.43 6.28
Net Cash From Investing Activities
0.00 -0.25 -0.54 0.00 -15 -2.03
Net Cash From Continuing Investing Activities
0.00 -0.25 -0.54 0.00 -15 -2.03
Purchase of Property, Plant & Equipment
- 0.00 -0.04 0.00 -0.01 -0.03
Acquisitions
0.00 -0.25 -0.50 0.00 -15 -2.00
Net Cash From Financing Activities
1.15 58 -0.10 0.00 109 -0.02
Net Cash From Continuing Financing Activities
1.15 58 -0.10 0.00 109 -0.02
Repurchase of Common Equity
- 0.00 -0.10 - 0.00 -0.02
Issuance of Common Equity
0.00 53 - 0.00 109 0.00

Quarterly Cash Flow Statements for Context Therapeutics

This table details how cash moves in and out of Context Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-4.36 91 -17 9.63 -5.08 -5.84 -6.58 -11 -11 -12 -8.58
Net Cash From Operating Activities
-4.36 -3.36 -1.93 -4.91 -5.03 -5.84 -6.58 -8.94 -11 -7.02 -6.58
Net Cash From Continuing Operating Activities
-4.36 -3.36 -1.93 -4.91 -5.03 -5.84 -6.58 -8.94 -11 -7.02 -6.58
Net Income / (Loss) Continuing Operations
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Consolidated Net Income / (Loss)
-3.67 -2.25 -17 -3.34 -4.58 -8.83 -9.69 -13 -8.68 -15 -7.62
Depreciation Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01
Amortization Expense
0.00 - 15 - 0.03 0.03 0.03 - 0.03 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income
0.24 0.16 0.21 15 0.29 0.39 0.32 2.43 0.41 7.03 0.46
Changes in Operating Assets and Liabilities, net
-0.94 -1.26 0.54 -1.78 -0.77 2.57 2.76 1.73 -3.19 0.47 0.54
Net Cash From Investing Activities
0.00 - -15 - -0.03 - - -2.00 -0.04 -4.52 -2.00
Net Cash From Continuing Investing Activities
0.00 - -15 - -0.03 - - -2.00 -0.04 -4.52 -2.00
Acquisitions
- - - - - - - -2.00 - - -2.00

Annual Balance Sheets for Context Therapeutics

This table presents Context Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.47 51 38 16 98 68
Total Current Assets
0.30 51 38 16 98 68
Cash & Equivalents
0.29 50 35 14 94 66
Prepaid Expenses
0.01 1.62 2.36 1.60 3.47 2.36
Plant, Property, & Equipment, net
0.00 0.00 0.03 0.02 0.01 0.03
Total Noncurrent Assets
0.17 0.05 0.08 0.00 0.22 0.11
Other Noncurrent Operating Assets
0.17 0.05 0.08 0.00 0.22 0.11
Total Liabilities & Shareholders' Equity
0.47 51 38 16 98 68
Total Liabilities
9.62 3.03 3.21 4.19 2.86 8.02
Total Current Liabilities
9.55 3.03 3.21 4.19 2.75 8.02
Accounts Payable
2.71 1.83 0.94 2.38 1.45 2.53
Accrued Expenses
0.96 1.21 2.22 1.81 1.19 5.38
Other Current Liabilities
- 0.00 0.06 0.00 0.11 0.11
Total Noncurrent Liabilities
0.07 0.00 0.00 0.00 0.11 0.00
Other Noncurrent Operating Liabilities
- - - 0.00 0.11 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-17 48 35 12 95 60
Total Preferred & Common Equity
-17 48 35 12 95 60
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-17 48 35 12 95 60
Common Stock
1.88 78 79 80 190 191
Retained Earnings
-19 -29 -44 -68 -95 -131

Quarterly Balance Sheets for Context Therapeutics

This table presents Context Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
23 11 103 86 93 87 79 59 46 37
Total Current Assets
23 11 103 86 93 87 79 59 46 36
Cash & Equivalents
22 10 102 85 89 84 77 55 43 34
Prepaid Expenses
1.29 0.95 1.16 1.27 3.38 3.43 2.12 3.99 2.83 1.86
Plant, Property, & Equipment, net
0.02 0.01 0.01 0.01 0.04 0.04 0.03 0.06 0.07 0.07
Total Noncurrent Assets
0.00 0.00 0.00 0.24 0.19 0.17 0.14 0.28 0.24 0.20
Other Noncurrent Operating Assets
0.00 - - - - - - - - 0.20
Total Liabilities & Shareholders' Equity
23 11 103 86 93 87 79 59 46 37
Total Liabilities
4.60 2.61 1.60 2.47 1.98 4.61 6.06 6.66 7.96 5.53
Total Current Liabilities
4.60 2.61 1.60 2.33 1.90 4.56 6.04 6.53 7.88 5.50
Accounts Payable
1.83 2.05 0.61 1.03 1.00 2.40 2.72 2.47 3.29 1.60
Accrued Expenses
2.78 0.56 0.99 1.20 0.79 2.04 3.20 3.91 4.43 3.73
Other Current Liabilities
0.00 - - 0.10 0.11 0.11 0.12 0.16 0.17 0.18
Total Noncurrent Liabilities
0.00 0.00 0.00 0.14 0.08 0.05 0.02 0.12 0.08 0.03
Other Noncurrent Operating Liabilities
- - - 0.14 0.08 0.05 0.02 0.12 0.08 0.03
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
18 8.44 101 84 91 83 73 52 38 31
Total Preferred & Common Equity
18 8.44 101 84 91 83 73 52 38 31
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
18 8.44 101 84 91 83 73 52 38 31
Common Stock
80 80 175 175 190 191 191 192 192 193
Retained Earnings
-61 -72 -74 -91 -99 -108 -118 -140 -154 -162

Annual Metrics And Ratios for Context Therapeutics

This table displays calculated financial ratios and metrics derived from Context Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 10,963,966.00 15,966,053.00 15,966,053.00 74,998,312.00 91,879,177.00
DEI Adjusted Shares Outstanding
0.00 10,963,966.00 15,966,053.00 15,966,053.00 74,998,312.00 91,879,177.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.95 -0.93 -1.50 -0.36 -0.39
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -243.95% -46.19% -63.37% -19.10% -32.00%
EBIT Growth
0.00% -243.95% -46.28% -63.35% -19.09% -32.00%
NOPAT Growth
0.00% -186.45% -46.13% -63.01% -19.35% -32.68%
Net Income Growth
0.00% -257.38% -41.88% -61.53% -11.52% -35.17%
EPS Growth
0.00% 6.82% 74.80% -61.29% 69.33% 17.39%
Operating Cash Flow Growth
0.00% -750.50% -53.98% -55.34% 30.84% -81.26%
Free Cash Flow Firm Growth
0.00% 0.00% -20.00% -37.93% -55.06% 12.02%
Invested Capital Growth
0.00% 60.92% 45.77% -248.92% 132.44% -760.12%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -5.41% -14.12% 8.24% -31.24%
EBIT Q/Q Growth
0.00% 0.00% -5.43% -14.11% 8.24% -31.23%
NOPAT Q/Q Growth
0.00% 0.00% -5.42% -13.85% 8.06% -31.43%
Net Income Q/Q Growth
0.00% 0.00% -3.24% -15.48% 11.37% -36.62%
EPS Q/Q Growth
0.00% 0.00% -105.70% -15.38% 49.45% -80.95%
Operating Cash Flow Q/Q Growth
0.00% -119.23% 7.08% -18.58% 13.75% -18.06%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -16.56% 3.06% -16.96%
Invested Capital Q/Q Growth
0.00% 0.00% 45.48% 21.67% 188.61% -46.69%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 98.83% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
90.95% 100.61% 96.44% 95.37% 89.31% 91.45%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-72.62% -53.46% -35.74% -102.79% -49.89% -46.39%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -2,912.59% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-134.29% -42.84% -35.74% -102.79% -49.89% -46.39%
Return on Equity Simple (ROE_SIMPLE)
-39.27% -21.66% -42.68% -201.87% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.57 -7.37 -11 -18 -21 -28
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-162.76% -14.05% -9.56% -25.68% -10.61% -10.39%
Return On Investment Capital (ROIC_SIMPLE)
- - - -147.85% -21.99% -45.96%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
7.31 -11 -15 -25 -30 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
7.31 -11 -15 -25 -30 -39
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.60 0.30 1.52 0.83 2.23
Price to Tangible Book Value (P/TBV)
0.00 0.60 0.30 1.52 0.83 2.23
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
3.76 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
26.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
5.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
5.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
-0.65 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.62 -1.12 -1.03 -1.07 -1.02 -1.03
Leverage Ratio
-0.05 1.32 1.08 1.16 1.07 1.07
Compound Leverage Factor
-0.05 1.33 1.04 1.11 0.95 0.98
Debt to Total Capital
-186.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
-184.09% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-2.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-243.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
529.36% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.81 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.78 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-2.31 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-2.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.03 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-26.91 5.42 0.08 -7.63 15.32 6.58
Noncontrolling Interest Sharing Ratio
-84.93% 19.86% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.03 16.90 11.80 3.83 35.62 8.52
Quick Ratio
0.03 16.36 11.07 3.45 34.36 8.23
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -9.49 -11 -16 -24 -21
Operating Cash Flow to CapEx
0.00% 0.00% -36,782.59% 0.00% -198,967.11% -77,722.93%
Free Cash Flow to Firm to Interest Expense
0.00 -147.76 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-1.56 -136.98 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-1.56 -136.98 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-3.49 -1.36 -0.74 -2.58 0.84 -5.52
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 2.12 0.62 -1.84 3.42 -6.36
Enterprise Value (EV)
38 -20 -25 3.59 -16 69
Market Capitalization
25 29 10 18 79 135
Book Value per Share
($48.57) $4.40 $2.18 $0.74 $1.27 $0.66
Tangible Book Value per Share
($48.57) $4.40 $2.18 $0.74 $1.27 $0.66
Total Capital
-3.20 48 35 12 95 60
Total Debt
5.95 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.07 0.00 0.00 0.00 0.00 0.00
Net Debt
5.66 -50 -35 -14 -94 -66
Capital Expenditures (CapEx)
0.00 0.00 0.04 0.00 0.01 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.66 -1.41 -0.85 -2.59 0.72 -5.66
Debt-free Net Working Capital (DFNWC)
-3.36 48 35 12 95 60
Net Working Capital (NWC)
-9.25 48 35 12 95 60
Net Nonoperating Expense (NNE)
-9.22 3.09 4.07 6.41 5.78 8.33
Net Nonoperating Obligations (NNO)
5.66 -50 -35 -14 -94 -66
Total Depreciation and Amortization (D&A)
0.00 0.00 0.01 0.01 0.01 0.02
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding
0.00 2.83M 15.97M 15.97M 58.42M 95.19M
Adjusted Diluted Earnings per Share
$0.00 ($3.69) ($0.93) ($1.50) ($0.46) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 2.83M 15.97M 15.97M 58.42M 95.19M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 15.97M 15.97M 15.97M 89.70M 91.88M
Normalized Net Operating Profit after Tax (NOPAT)
-1.80 -7.37 -11 -18 -21 -28
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
11.05 -163.71 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-3.89 -114.70 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
11.05 -163.71 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-3.89 -114.70 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -0.69% 0.00% 0.00% -0.04%

Quarterly Metrics And Ratios for Context Therapeutics

This table displays calculated financial ratios and metrics derived from Context Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
15,966,053.00 74,998,312.00 74,998,312.00 74,998,312.00 89,704,194.00 89,704,194.00 89,704,194.00 91,879,177.00 91,879,177.00 91,879,177.00 91,879,177.00
DEI Adjusted Shares Outstanding
15,966,053.00 74,998,312.00 74,998,312.00 74,998,312.00 89,704,194.00 89,704,194.00 89,704,194.00 91,879,177.00 91,879,177.00 91,879,177.00 91,879,177.00
DEI Earnings Per Adjusted Shares Outstanding
-0.23 -0.03 -0.23 -0.04 -0.05 -0.10 -0.11 -0.14 -0.09 -0.16 -0.08
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
42.49% 41.43% 36.08% 38.44% -44.22% -213.72% -166.77% -218.40% -66.46% -53.93% 24.65%
EBIT Growth
42.67% 41.66% -203.38% 38.42% -44.91% -214.45% 43.72% -218.28% -66.20% -53.91% 24.43%
NOPAT Growth
42.65% 41.64% -202.59% 37.83% -44.61% -215.95% 43.26% -220.26% -68.99% -53.38% 24.97%
Net Income Growth
41.86% 55.01% -197.21% 50.62% -24.80% -291.55% 44.48% -289.65% -89.65% -64.92% 21.35%
EPS Growth
42.50% 87.10% 40.54% 107.14% 78.26% -125.00% 54.55% -566.67% -80.00% -66.67% 20.00%
Operating Cash Flow Growth
23.88% 27.54% 44.14% 32.11% -15.31% -73.89% -240.29% -82.26% -127.30% -20.30% -0.01%
Free Cash Flow Firm Growth
47.45% 25.35% -546.04% -113.46% -245.82% -119.72% 70.16% 48.62% 63.85% -5.42% -28.74%
Invested Capital Growth
-58.85% 61.85% 71.33% 132.44% 199.06% -125.00% -298.76% -760.12% -242.67% -395.34% 9.52%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
45.40% 19.00% -27.24% -9.40% -27.92% -76.19% -8.20% -30.57% 33.12% -62.93% 47.04%
EBIT Q/Q Growth
45.38% 18.99% -504.38% 76.97% -28.53% -75.79% -8.18% -30.22% 32.88% -62.78% 46.88%
NOPAT Q/Q Growth
44.85% 19.22% -505.51% 76.95% -28.27% -76.49% -8.73% -30.10% 32.31% -60.19% 46.81%
Net Income Q/Q Growth
45.82% 38.53% -674.44% 80.85% -36.92% -92.86% -9.81% -34.38% 33.36% -67.71% 47.63%
EPS Q/Q Growth
45.24% 82.61% -450.00% 113.64% -266.67% -80.00% -11.11% -40.00% 35.71% -66.67% 46.67%
Operating Cash Flow Q/Q Growth
39.66% 23.04% 42.39% -153.80% -2.48% -16.04% -12.74% -35.93% -27.80% 38.58% 6.27%
Free Cash Flow Firm Q/Q Growth
31.42% -38.53% -439.28% 58.34% -11.10% 11.98% 26.76% 28.26% 21.82% -156.65% 10.56%
Invested Capital Q/Q Growth
36.17% 73.73% -118.34% 188.61% 94.93% -159.66% -286.96% -46.69% 57.87% -107.13% 29.32%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
96.01% 72.85% 93.35% 77.62% 82.69% 90.71% 92.08% 95.02% 94.35% 97.20% 95.83%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-114.72% -29.68% -58.98% -49.89% -55.59% -37.25% -33.68% -46.39% -56.19% -76.14% -84.26%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -2,912.59% -1,558.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-114.72% -29.68% -58.98% -49.89% -55.59% -37.25% -33.68% -46.39% -56.19% -76.14% -84.26%
Return on Equity Simple (ROE_SIMPLE)
-252.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.68 -2.16 -13 -3.02 -3.87 -6.83 -7.43 -9.66 -6.54 -10 -5.57
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.97% -0.15% -8.21% -0.60% -1.42% -2.16% -2.80% -4.19% -2.97% -6.45% -3.68%
Return On Investment Capital (ROIC_SIMPLE)
-31.70% -2.14% -15.61% -3.17% -4.25% -8.28% -10.15% -15.98% -12.53% -27.45% -17.97%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.82 -3.09 -19 -4.31 -5.54 -9.73 -11 -14 -9.20 -15 -7.96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.82 -3.09 -3.93 -4.30 -5.51 -9.70 -10 -14 -9.16 -15 -7.91
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.61 1.49 1.75 0.83 0.60 0.71 1.19 2.23 4.61 1.33 0.89
Price to Tangible Book Value (P/TBV)
2.61 1.49 1.75 0.83 0.60 0.71 1.19 2.23 4.61 1.33 0.89
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.07 -1.01 -1.04 -1.02 -1.00 -1.01 -1.03 -1.03 -1.00 -1.05 -1.07
Leverage Ratio
1.16 1.04 1.07 1.07 1.05 1.03 1.05 1.07 1.06 1.10 1.11
Compound Leverage Factor
1.11 0.76 1.00 0.83 0.87 0.94 0.97 1.02 1.00 1.07 1.06
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-4.24 56.31 34.64 16.18 16.09 6.68 7.19 7.83 18.92 -0.93 -2.91
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.23 64.01 36.91 35.62 48.80 19.09 13.10 8.52 8.96 5.81 6.59
Quick Ratio
3.87 63.29 36.36 34.36 47.02 18.33 12.75 8.23 8.34 5.45 6.26
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.07 -2.86 -15 -6.43 -7.15 -6.29 -4.61 -3.31 -2.58 -6.63 -5.93
Operating Cash Flow to CapEx
0.00% 0.00% -26,426.03% 0.00% -14,812.01% 0.00% 0.00% 0.00% -30,676.30% -37,969.15% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.65 -0.43 -0.94 0.84 1.63 -0.97 -3.76 -5.52 -2.33 -4.82 -3.41
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.61 0.70 2.35 3.42 3.28 -0.54 -2.82 -6.36 -3.96 -3.85 0.36
Enterprise Value (EV)
12 49 62 -16 -34 -25 9.97 69 186 7.90 -6.81
Market Capitalization
22 150 147 79 55 59 87 135 241 51 28
Book Value per Share
$0.53 $1.35 $1.12 $1.27 $1.01 $0.92 $0.82 $0.66 $0.57 $0.42 $0.34
Tangible Book Value per Share
$0.53 $1.35 $1.12 $1.27 $1.01 $0.92 $0.82 $0.66 $0.57 $0.42 $0.34
Total Capital
8.44 101 84 95 91 83 73 60 52 38 31
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-10 -102 -85 -94 -89 -84 -77 -66 -55 -43 -34
Capital Expenditures (CapEx)
0.00 0.00 0.01 0.00 0.03 0.00 0.00 0.00 0.04 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.66 -0.44 -1.06 0.72 1.48 -1.12 -3.92 -5.66 -2.55 -5.06 -3.64
Debt-free Net Working Capital (DFNWC)
8.43 101 84 95 91 82 73 60 52 38 31
Net Working Capital (NWC)
8.43 101 84 95 91 82 73 60 52 38 31
Net Nonoperating Expense (NNE)
0.99 0.09 4.37 0.33 0.71 2.00 2.27 3.36 2.14 4.08 2.05
Net Nonoperating Obligations (NNO)
-10 -102 -85 -94 -89 -84 -77 -66 -55 -43 -34
Total Depreciation and Amortization (D&A)
0.00 0.00 15 0.00 0.03 0.03 0.03 0.00 0.04 0.05 0.05
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09) ($0.15) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding
15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M 95.18M 95.18M
Adjusted Diluted Earnings per Share
($0.23) ($0.04) ($0.22) $0.03 ($0.05) ($0.09) ($0.10) ($0.14) ($0.09) ($0.15) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding
15.97M 54.96M 80.48M 58.42M 95.19M 95.19M 95.19M 95.19M 95.18M 95.18M 95.18M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
75.00M 75.00M 75.00M 89.70M 89.70M 89.70M 91.88M 91.88M 91.88M 91.88M 91.88M
Normalized Net Operating Profit after Tax (NOPAT)
-2.68 -2.16 -13 -3.02 -3.87 -6.83 -7.43 -9.66 -6.54 -10 -5.57
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Context Therapeutics (NASDAQ:CNTX) remains a development-stage biotechnology company with no reported revenue. Every income statement in the provided period shows zero revenue and zero gross profit. The company continues to fund its pipeline through cash on hand and equity capital rather than product sales or operating cash flow.

Liquidity has weakened substantially. Cash and equivalents declined from $101.5 million in Q2 2024 to $43.0 million in Q2 2026. The company reported a $7.0 million operating cash outflow and a $4.5 million investing cash outflow in Q2 2026, resulting in an $11.5 million quarterly reduction in cash. At that recent total cash-burn rate, the existing cash balance represents roughly four quarters of funding, although actual runway will depend on clinical spending, financing activity and investment proceeds.

The balance sheet still has some strengths. Q2 2026 current assets of $45.8 million exceeded current liabilities of $7.9 million by a wide margin, and total liabilities of $8.0 million remained modest compared with total assets of $46.1 million. However, total equity fell from $101.1 million in Q2 2024 to $38.2 million in Q2 2026, while accumulated retained losses reached $154.1 million.

  • Low leverage: CNTX reported no preferred stock and relatively limited liabilities, with total liabilities of $8.0 million versus $46.1 million of assets in Q2 2026.
  • Current liquidity remains adequate in the near term: Q2 2026 current assets were approximately 5.8 times current liabilities, providing a meaningful cushion for near-term obligations.
  • Interest and investment income provides partial support: The company generated $418,663 of interest and investment income in Q2 2026, helping reduce the quarter’s pretax loss, although this income is not a substitute for operating revenue.
  • Research spending is funding pipeline development: R&D expense increased to $12.5 million in Q2 2026 from $7.8 million in Q2 2024, indicating greater investment in the company’s clinical programs but also increasing the need for successful development milestones.
  • Capital expenditures are minimal: Q2 2026 purchases of property and equipment were only $18,488, suggesting that the company’s cash needs are primarily related to research, clinical development and corporate operations rather than physical infrastructure.
  • No commercial revenue has been reported: Revenue and gross profit were both zero in each supplied quarter, leaving CNTX without a recurring operating source of cash.
  • Net losses are becoming larger: The Q2 2026 net loss was $14.6 million, compared with $8.8 million in Q2 2025 and $2.3 million in Q2 2024. Basic loss per share widened to $0.15 from $0.04 two years earlier.
  • Operating expenses have risen sharply: Total operating expenses reached $15.0 million in Q2 2026, up from $9.8 million in Q2 2024. R&D accounted for most of the latest quarter’s spending, while SG&A also increased to $2.4 million.
  • Cash burn is persistent: Operating cash flow was negative in every supplied quarter. The Q2 2026 operating outflow of $7.0 million was supplemented by a $4.5 million investing outflow, producing a total quarterly cash decline of $11.5 million.
  • Future financing and dilution remain important risks: CNTX has historically relied on equity financing, and common stock balances have increased while the company continues to accumulate losses. Additional capital raises could dilute existing shareholders if cash generation does not improve.
11/22/26 09:15 AM ETAI Generated. May Contain Errors.

Context Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Context Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Context Therapeutics' net income appears to be on a downward trend, with a most recent value of -$36.12 million in 2025, compared with $6.64 million in 2020. The previous period was -$26.73 million in 2024. Find out what analysts predict for Context Therapeutics in the coming months.

Context Therapeutics' total operating income in 2025 was -$39.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $39.70 million

Over the last 5 years, Context Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Context Therapeutics' cash and equivalents has ranged from $10.09 million in Q1 2024 to $101.54 million in Q2 2024, and is currently $34.41 million as of their latest financial filing in Q3 2026.

Context Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2020.

Over the last 5 years, Context Therapeutics' book value per share changed from -48.57 in 2020 to 0.66 in 2025.



Financial statements for NASDAQ:CNTX last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners